<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864990</url>
  </required_header>
  <id_info>
    <org_study_id>2019_62</org_study_id>
    <secondary_id>2020-A00803-36</secondary_id>
    <nct_id>NCT04864990</nct_id>
  </id_info>
  <brief_title>Dyspnea and Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>DYS-PID</acronym>
  <official_title>Dyspnea in Idiopathic Pulmonary Fibrosis (IPF): Multidimensional Assessment and Correlations With Lung Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santelys Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal prospective exploratory study on the evolution of dyspnea, in its sensory and&#xD;
      affective dimensions, in patients followed for idiopathic pulmonary fibrosis (IPF), between&#xD;
      inclusion and a 6-month evaluation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dyspnea is a multidimensional experience involving a sensory component and an affective&#xD;
      component. To better understand this symptom in IPF, this study will describe the different&#xD;
      component of dyspnea and their evolution between inclusion and a 6-month evaluation in IPF&#xD;
      patients.&#xD;
&#xD;
      There is no strong correlation between the intensity of dyspnea and respiratory function&#xD;
      impairments. Innovative techniques demonstrated abnormalities in ventilation variability and&#xD;
      pulmonary compliance in patients with interstitial lung disease. These abnormalities could be&#xD;
      more relevant to explain dyspnea. The objective of this work is also to assess the link&#xD;
      between the different dimensions of dyspnea and respiratory functional parameters,&#xD;
      ventilation variability and ventilatory mechanics measured by impulse oscillometry technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the sensory and affective components of dyspnea</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Description and changes in sensory (SQ) and affective (A2) scores of the Multidimensional Dyspnea Profile (MDP) questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of dyspnea during activities of daily living</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Description and changes in San Diego Shortness of Breath Questionnaire (SOBQ) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the sensory and affective components of dyspnea and quality of life, anxiety symptoms, lung volumes, gas exchanges, ventilation variability, pulmonary compliance, pulmonary hypertension</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Correlation between SQ and A2 scores of the MDP questionnaire and King's Brief Interstitial Lung Disease (K-BILD) questionnaire score, State Trait Anxiety Inventory (STAI-Y2) score, lung volumes measured by plethysmography, DLCO, PaO2, delta of desaturation during the 6-minute walk test, coefficient of variation of the tidal volume at rest, impulse oscillometry reactance, systolic pulmonary artery pressure assessed by cardiac ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the prevalence of refractory dyspnea</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>Description of the prevalence of patients with visual anolog scale at rest &gt; 3 or mMRC scale &gt; 2</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients with a diagnosis of idiopathic pulmonary fibrosis (IPF) and reporting dyspnea&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of IPF according to ATS/ERS guidelines&#xD;
&#xD;
          -  dyspnea at rest (VAS ≥ 1) or on exertion (mMRC ≥ 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diffuse interstitial lung disease other than IPF&#xD;
&#xD;
          -  other significant chronic pathology that may cause dyspnea: chronic obstructive&#xD;
             pulmonary disease, asthma, heart failure, anemia, obesity (non-exhaustive list),&#xD;
             except for pulmonary hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile Chenivesse, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Chenivesse, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>cecile.chenivesse@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Calmette Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

